UCB (OTCMKTS:UCBJF) Trading Down 5.8% – Here’s Why

UCB SA (OTCMKTS:UCBJF)’s stock price traded down 5.8% during trading on Thursday . The company traded as low as $289.00 and last traded at $289.00. 116 shares were traded during trading, a decline of 85% from the average session volume of 783 shares. The stock had previously closed at $306.94.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on UCBJF shares. Wolfe Research began coverage on shares of UCB in a report on Monday, February 23rd. They issued an “outperform” rating on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a report on Monday, February 16th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, UCB currently has a consensus rating of “Buy”.

UCB Stock Up 0.9%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average of $294.91 and a 200 day moving average of $297.56.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.